CEL-SCI Corporation (CVM) Bundle
A Brief History of CEL-SCI Corporation (CVM)
Company Formation
CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia. It focuses on developing immunotherapy treatments for cancer and other diseases.
Key Developments
In the early 1990s, CEL-SCI initiated research on its lead product, LEAPS technology, targeting immune responses. The company first entered the public market in 1992.
Product Pipeline
The company is primarily known for its product Multikine (Leukocyte Interleukin Injection), a cancer immunotherapy that has been investigated for head and neck cancer. In 2020, CEL-SCI reported that it had completed patient enrollment for a Phase III clinical trial of Multikine.
| Year | Milestone | Details |
|---|---|---|
| 1992 | IPO | CEL-SCI went public, trading on NASDAQ under the symbol CVM. |
| 2015 | Phase III Trials | Started a pivotal Phase III trial for Multikine; expected to enroll 800 patients. |
| 2020 | Trial Completion | Announced completion of patient enrollment for Phase III trial of Multikine. |
| 2022 | Results Announcement | Expected interim results of the Phase III trial. |
Financial Overview
As of the end of 2022, CEL-SCI Corporation reported total assets of approximately $26.1 million. The company's revenue for the year was notably low, primarily due to its ongoing development phase, with reported revenues of $500,000.
Stock Performance
As of October 2023, CEL-SCI Corporation’s stock is trading at approximately $4.50 per share, with a market capitalization of around $120 million.
| Metric | Value |
|---|---|
| Share Price (October 2023) | $4.50 |
| Market Capitalization | $120 million |
| Total Assets (End of 2022) | $26.1 million |
| Revenue (2022) | $500,000 |
Recent Developments
In 2023, CEL-SCI Corporation announced strategic partnerships aimed at enhancing the development and commercialization of its product pipeline, particularly focusing on Multikine.
Future Outlook
Looking ahead, CEL-SCI aims to advance its clinical trials and expand into new therapeutic areas, with ongoing innovations in cancer treatment and immunotherapy technologies.
A Who Owns CEL-SCI Corporation (CVM)
Shareholder Composition
Shareholder Composition
As of the latest available data, CEL-SCI Corporation has a range of institutional and individual shareholders. The following table outlines the major shareholders and their respective ownership percentages:
| Shareholder | Type | Shares Owned | Ownership Percentage |
|---|---|---|---|
| BlackRock, Inc. | Institutional | 2,000,000 | 5.3% |
| Vanguard Group, Inc. | Institutional | 1,850,000 | 4.9% |
| State Street Corporation | Institutional | 1,500,000 | 4.0% |
| Millennium Management LLC | Institutional | 1,100,000 | 2.9% |
| Individual Investors | Individual | 22,000,000 | 58.5% |
Insider Ownership
Insider ownership is a significant aspect of CEL-SCI Corporation's shareholder structure. The following table presents insiders' stock ownership:
| Insider | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Geert Kersten | CEO | 5,000,000 | 13.2% |
| Dr. Michael R. S. Reddy | Chief Scientific Officer | 1,200,000 | 3.2% |
| Linda K. Evans | CFO | 800,000 | 2.1% |
| Other Insiders | Various | 900,000 | 2.4% |
Market Capitalization
The market capitalization of CEL-SCI Corporation as of the latest stock market close is approximately $377 million.
Stock Performance
CEL-SCI Corporation's stock (CVM) has shown volatility in the market. The closing price on the last trading day was $6.35. The 52-week range has been from $4.00 to $8.50.
Recent Financial Metrics
The latest quarterly financial report indicates the following metrics:
| Metric | Value |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | ($5.3 million) |
| Cash and Cash Equivalents | $20 million |
| Total Assets | $40 million |
Recent Developments
- In October 2023, CEL-SCI Corporation announced results from its Phase 3 clinical trial.
- The company secured a partnership for the distribution of its product in Europe.
- Recent presentations at oncology conferences have raised awareness regarding its cancer immunotherapy.
Conclusion on Ownership Distributions and Market Activity
The overall ownership structure of CEL-SCI Corporation reflects a mix of institutional and individual investors, with significant insider ownership. The company is actively engaged in clinical development, aiming to leverage its research for future growth in a competitive market.
CEL-SCI Corporation (CVM) Mission Statement
Company Overview
CEL-SCI Corporation (CVM), headquartered in Vienna, Virginia, is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's mission centers on enhancing the immune response to fight cancer and infectious diseases.
Mission Statement
The driving mission of CEL-SCI Corporation is to improve the lives of patients by leveraging the body’s immune system to combat diseases, particularly cancer, through innovative therapies.
Core Values
- Innovation: Commit to pioneering research and development in the field of immunotherapy.
- Integrity: Conduct business and scientific endeavors with the utmost ethical standards.
- Patient-Centric: Focus on patients' needs and outcomes in every aspect of development.
- Collaboration: Foster partnerships with researchers, healthcare professionals, and patients
Strategic Objectives
CEL-SCI Corporation aims to achieve the following strategic objectives:
- Develop and commercialize groundbreaking immunotherapy products.
- Enhance patient survival rates and quality of life.
- Expand collaborations with industry partners and academic institutions.
- Achieve regulatory approvals for innovative treatments.
Recent Financial Performance
As of the latest fiscal year-end, CEL-SCI Corporation reported the following financial metrics:
| Metric | Value (USD) |
|---|---|
| Revenue | 1.05 million |
| Net Loss | (15.2 million) |
| Total Assets | 25.3 million |
| Total Liabilities | 6.9 million |
| Cash and Cash Equivalents | 23.1 million |
Key Products and Developments
CVM's pivotal product, Multikine, is an investigational immunotherapy designed for the treatment of head and neck cancer. The mission includes:
- Advancing Multikine through clinical trials.
- Exploring additional indications and combination therapies.
- Driving product awareness and stakeholder engagement.
Market Position
CEL-SCI is positioned in the biotechnology market where the demand for innovative cancer therapies is rapidly increasing. Key competitors include:
| Competitor | Market Capitalization (USD) |
|---|---|
| ImmunoGen, Inc. | 440 million |
| Amgen Inc. | 120.2 billion |
| Theravance Biopharma, Inc. | 575 million |
Research and Development Focus
The company's ongoing R&D projects are aligned with its mission, focusing on:
- Immunotherapy mechanism enhancements.
- Advanced cancer treatment modalities.
- Potential applications for other diseases.
Future Goals
CEL-SCI Corporation's ambitions for the coming years include:
- Completing Phase III clinical trials for Multikine.
- Expanding its immunotherapy pipeline.
- Seeking partnerships for commercialization.
How CEL-SCI Corporation (CVM) Works
Company Overview
Company Overview
CEL-SCI Corporation, trading under the ticker CVM, is a biotechnology company based in Vienna, Virginia. It focuses on the research and development of immunotherapy treatments for cancer and infectious diseases. The company is particularly known for its lead product candidate, Multikine, a therapeutic agent aimed at treating head and neck cancer.
Business Model
The company operates primarily through the development of its proprietary products. CEL-SCI collaborates with academic institutions and research organizations to enhance its drug development processes.
Key Products
-
Multikine: An investigational drug targeting head and neck cancer.
-
LEAPS: A platform technology aimed at activating the immune response against various diseases.
Research and Development
- Multikine: An investigational drug targeting head and neck cancer.
- LEAPS: A platform technology aimed at activating the immune response against various diseases.
Research and Development
CEL-SCI's R&D efforts are strongly focused on the clinical development of Multikine. As of 2023, the company has been conducting Phase III clinical trials for Multikine in patients with advanced primary head and neck cancer.
Financial Performance
| Financial Metric | 2023 Amount (Q2) | 2022 Amount (Q2) | % Change |
|---|---|---|---|
| Revenue | $5.1 million | $1.2 million | 325% |
| Net Loss | ($3.6 million) | ($4.5 million) | 20% |
| Cash and Cash Equivalents | $23.4 million | $12.5 million | 87% |
Clinical Trials
CEL-SCI is known for its rigorous clinical trial processes. As of October 2023, the company reported the following statistics regarding its Multikine trials:
| Trial Phase | Number of Patients | Location | Status |
|---|---|---|---|
| Phase III | 800 | United States, Europe | Ongoing |
| Phase II | 150 | Canada | Completed |
Market Potential
The global immunotherapy market is projected to grow from $80 billion in 2022 to $165 billion by 2027. CEL-SCI aims to capture a share of this market through the successful commercialization of Multikine and other immunotherapy products.
Strategic Partnerships
-
Partnership with leading research institutions for collaborative studies on immune response.
-
Collaborations with pharmaceutical companies for potential distribution agreements.
Stock Performance
- Partnership with leading research institutions for collaborative studies on immune response.
- Collaborations with pharmaceutical companies for potential distribution agreements.
Stock Performance
As of October 2023, the stock price for CVM has shown significant volatility:
| Date | Price | Change (%) |
|---|---|---|
| October 2023 | $8.50 | +15% |
| September 2023 | $7.39 | +10% |
Future Outlook
CEL-SCI projects to advance its Phase III clinical trials and expects to report further data outcomes within the next 12 months. The company is optimistic about the potential approval and market introduction of Multikine.
How CEL-SCI Corporation (CVM) Makes Money
Overview of CEL-SCI Corporation
CEL-SCI Corporation, established in 1983, is a biotechnology company focused on the development of immunotherapy treatments for cancer and other diseases. The company’s lead product candidate is Multikine, an investigational immunotherapy designed to treat head and neck cancer.
Revenue Generation Methods
The primary revenue generation methods for CEL-SCI include:
- Licensing agreements
- Collaborative partnerships
- Grants and funding
- Potential sales of approved therapeutics
Licensing Agreements
CEL-SCI holds licensing agreements that allow other companies to utilize its technology and products. A notable agreement is with Helsinn Healthcare, which was signed in 2021 and could bring in up to $200 million depending on product milestones.
Collaborative Partnerships
Strategic partnerships often provide funding and resources, crucial for research and development. For instance, the collaboration with United Therapeutics Corporation for the development of Multikine has the potential to yield significant financial returns.
Research Grants and Funding
CEL-SCI has received various grants from government and non-profit entities. In 2022, they were awarded a grant of $1.8 million from the National Cancer Institute for research purposes.
Financial Performance
| Year | Total Revenue | Research and Development Expenses | Net Income (Loss) |
|---|---|---|---|
| 2020 | $1.2 million | $7.5 million | -$6.3 million |
| 2021 | $1.6 million | $8.2 million | -$6.6 million |
| 2022 | $2.0 million | $10.5 million | -$8.2 million |
| 2023 (Q1) | $0.5 million | $2.0 million | -$1.5 million |
Market Potential of Multikine
The potential market for Multikine is substantial, given the incidence of head and neck cancers. In the United States alone, approximately 54,540 new cases are reported annually, with the global market estimated to reach $5 billion by 2027 for head and neck cancer therapeutics.
Investor Relations and Stock Performance
As of October 2023, CEL-SCI Corporation's stock price is approximately $5.50 per share, with a market capitalization of around $300 million. The company’s trading volume averages 500,000 shares per day, indicating significant investor interest.
Future Financial Outlook
The financial outlook for CEL-SCI heavily relies on the success of Multikine in clinical trials and subsequent approval for market use. Analysts predict that if approved, annual revenues could exceed $200 million within five years post-launch.
CEL-SCI Corporation (CVM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support